Moderna and Merck will start a phase 3 trial of the combination in adjuvant melanoma therapy later this year, and the proof-of-concept for this personalised neoantigen vaccine approach means that ...

Optimal Synergetic Operation and Experimental Evaluation of an Ultracompact GaN-Based Three-Phase 10-kW EV Charger ...